

Contact: Doug Guarino  
Jon Russell

Director of Corporate Relations  
Vice President of Finance

781-647-3900

**ALERE INC. ANNOUNCES  
THIRD QUARTER 2012 RESULTS**

---

**WALTHAM, MA...November 8, 2012...Alere Inc.** (NYSE: **ALR**), a global leader in enabling individuals to take charge of their health at home through the merger of rapid diagnostics and health management, today announced its financial results for the quarter ended September 30, 2012.

**Financial results for the third quarter of 2012:**

- Net revenue of \$691.4 million for the third quarter of 2012, compared to \$585.8 million for the third quarter of 2011. Non-GAAP adjusted net revenue, which includes \$0.9 million in estimated revenue related to acquired software license contracts not recognized for GAAP purposes for the third quarter of 2012 due to business combination accounting rules, was \$692.3 million for the third quarter of 2012, compared to \$585.8 million for the third quarter of 2011.
- Net loss of \$9.2 million attributable to common stockholders of Alere Inc., and respective net loss per diluted common share of \$0.11, for the third quarter of 2012, compared to net income of \$234.2 million attributable to common stockholders of Alere Inc., and respective net income per diluted common share of \$2.48, for the third quarter of 2011. Net income for the third quarter of 2011 included a gain of \$288.9 million in connection with the formation of our joint venture with the Procter & Gamble Company.
- Non-GAAP adjusted net income per diluted common share of \$0.43 for the third quarter of 2012, compared to non-GAAP adjusted net income per diluted common share of \$0.67 for the third quarter of 2011.
- Net product and services revenue from our Professional Diagnostics segment was \$528.8 million in the third quarter of 2012, compared to net product and services revenue of \$426.3 million in the third quarter of 2011. Non-GAAP adjusted net product and services revenue from our Professional Diagnostics segment, which includes \$0.9 million in estimated revenue related to acquired software license contracts not recognized for GAAP purposes for the third quarter of 2012 due to business combination accounting rules, was \$529.7 million in the third quarter of 2012, compared to non-GAAP adjusted net product and services revenue of \$426.3 million in the third quarter of 2011. Recent professional diagnostics acquisitions contributed \$134.6 million of incremental net revenue compared to the third quarter of 2011.
- North American influenza sales decreased to \$9.9 million for the third quarter of 2012, from

\$16.0 million for the third quarter of 2011.

- Excluding the impact of the change in North American influenza revenues and the impact on revenues of the FDA matters associated with our U.S. Alere Triage products, currency adjusted organic growth in our Professional Diagnostics segment was 1%.
- Net product and services revenue from our Health Management segment was \$135.1 million in the third quarter of 2012, compared to \$129.9 million in the third quarter of 2011 and \$138.6 million in the second quarter of 2012. The increase in revenue from the third quarter of 2011 was related primarily to increased revenues from our home coagulation monitoring programs.

The Company's GAAP results for the third quarter of 2012 exclude \$0.9 million of revenue associated with acquired software license contracts that are not recognized due to business combination accounting rules and include amortization of \$83.1 million, \$3.3 million of restructuring charges, \$3.6 million of stock-based compensation expense, \$0.8 million of acquisition-related costs recorded in accordance with ASC 805, *Business Combinations*, and \$1.3 million of amortization associated with fees paid for certain debt modifications and terminations, offset by \$15.1 million of income recorded for fair value adjustments to acquisition-related contingent consideration. The Company's GAAP results for the third quarter of 2011 include amortization of \$70.3 million, \$3.4 million of restructuring charges, \$4.3 million of stock-based compensation expense, \$2.9 million of acquisition-related costs recorded in accordance with ASC 805, *Business Combinations*, \$1.3 million of amortization associated with fees paid for certain debt modifications and terminations, a \$0.6 million fair value write-down in connection with an idle facility and a net unrealized foreign currency loss of \$18.1 million associated with a bank account funded for the acquisition of Axis-Shield plc, offset by \$3.8 million of income recorded for fair value adjustments to acquisition-related contingent consideration and a \$288.9 million gain in connection with the formation of our joint venture with Procter & Gamble in May 2007. These amounts, net of tax, have been excluded from the non-GAAP adjusted net income per diluted common share attributable to Alere Inc. for the respective quarters.

Detailed reconciliations of the Company's non-GAAP adjusted operating income and non-GAAP adjusted net income available to common shareholders to operating income and net loss available to common shareholders under GAAP, as well as a discussion regarding these non-GAAP financial measures, is included in the schedules to this press release.

The Company will host a conference call beginning at 8:30 a.m. (Eastern Time) today, November 8, 2012, to discuss these results, as well as other corporate matters. During the conference call, the Company may answer questions concerning business and financial developments and trends and other

business and financial matters. The Company's responses to these questions, as well as other matters discussed during the conference call, may contain or constitute information that has not been previously disclosed.

The conference call may be accessed by dialing (877) 270-2148 (domestic) or (412) 902-6510 (international) and asking for Alere Inc. A webcast of the call can also be accessed via the Alere web site at [www.alere.com/investors](http://www.alere.com/investors), or directly through the following link: <http://www.videonewswire.com/event>.

A replay of the call will be available approximately one hour after the conclusion of the call and will remain available for a period of seven days following the call. The replay may be accessed by dialing (877) 344-7529 (domestic) or (412) 317-0088 (international) and entering replay code 10020552. The replay will also be available via online webcast at <http://www.videonewswire.com/event> or via the Alere web site at [www.alere.com/investors](http://www.alere.com/investors) for a period of 60 days following the call.

Additionally, reconciliations to non-GAAP financial measures not included in this press release that may be discussed during the call will also be available at the Alere web site (<http://www.alere.com/investors>) under the Earnings Calls and Releases section shortly before the conference call begins and will continue to be available on this web site.

For more information about Alere, please visit our web site at <http://www.alere.com>.

By developing new capabilities in near-patient diagnosis, monitoring and health management, Alere enables individuals to take charge of improving their health and quality of life at home. Alere's global leading products and services, as well as its new product development efforts, focus on cardiology, infectious disease, toxicology, diabetes, oncology and women's health. Alere is headquartered in Waltham, Massachusetts.

*Source: Alere Inc.*